# Equillium, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Equillium, Inc.). ## Overview Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe immuno-inflammatory diseases. Its pipeline has centered on itolizumab (EQ001), EQ504, EQ302 and earlier-stage programs, but the company has not yet commercialized a product and has paused R&D pending near-term financing needs. ## Products & services • Itolizumab (EQ001) for immuno-inflammatory indications • EQ504 preclinical program • EQ302 preclinical program • EQ101 and EQ102 earlier-stage development assets • Collaboration/licensing rights for future product candidates - **Clinical-stage immunology pipeline** (100%) — Drug candidates being developed for autoimmune and immuno-inflammatory diseases. - **Collaboration and licensing revenue** (0%) — Upfront payments, development funding, and potential future license economics from partners. - Itolizumab (EQ001) clinical development for immuno-inflammatory diseases - EQ504 preclinical development program - EQ302 preclinical development program - EQ101 and EQ102 earlier-stage pipeline assets - Collaboration and license agreements tied to pipeline monetization ## Customers Equillium does not currently sell approved products, so its near-term counterparties are primarily pharmaceutical partners, licensors, and research collaborators rather than end patients. If its candidates are approved, the eventual customers would be physicians, hospitals, and payors in specialty autoimmune and inflammatory disease markets. The company’s commercial model depends on partnering or building a sales capability later, which it does not yet have. - **Strategic collaboration partners** (primary) — Biopharma partners that fund development, license assets, or share commercialization rights. - **Clinical research ecosystem** (primary) — CROs, investigators, and trial sites that execute non-clinical and clinical development work. - **Future specialty prescribers** (emerging) — Physicians and hospitals that would use approved therapies in immuno-inflammatory indications. - **Healthcare payors** (emerging) — Commercial and government payors that would influence access and reimbursement after approval. - Pharma partners funding development or licensing rights - Clinical investigators and CROs supporting trials - Future physicians treating autoimmune/inflammatory disease - Hospitals and specialty clinics if products are approved - Payors and reimbursement systems that determine adoption ## Geography Equillium is headquartered in the United States and its disclosed commercial rights for itolizumab cover the U.S., Canada, Australia, and New Zealand. It also has an Australian subsidiary that can receive R&D tax incentive refunds, which makes Australia relevant to cash flow and expense recognition even though the company remains development-stage. The business is therefore geographically concentrated, with operational exposure tied to U.S. capital markets and partner-dependent development activity. - United States is the core operating and financing base - Commercial rights disclosed for U.S., Canada, Australia, and New Zealand - Australian subsidiary supports R&D tax incentive claims - No disclosed country revenue mix from product sales yet - Geography matters mainly through partner rights and tax refunds ## Strategy Equillium’s strategy is to preserve optionality around its immunology pipeline while seeking capital to restart development and advance EQ504, EQ302, and itolizumab. Management has said it may pursue equity, debt, and collaboration/licensing transactions, and if financing is not secured it may need strategic alternatives or an orderly wind-down. The company’s near-term focus is therefore financing survival rather than commercial expansion. - **Near-term financing** (short-term) — The company paused R&D and needs capital to continue operations and avoid strategic alternatives. - **Pipeline advancement** (medium-term) — Value creation depends on progressing EQ504, EQ302, and itolizumab toward clinical and regulatory milestones. - **Strategic optionality** (short-term) — If financing is unavailable, management may need mergers, asset transactions, or a wind-up. - Raise capital to restart paused R&D activities - Advance EQ504, EQ302, and itolizumab development - Use collaborations and licenses to fund the pipeline - Preserve rights while avoiding forced dilution or wind-down - Maintain optionality for mergers or strategic alternatives ## Risks Equillium is a loss-making, clinical-stage company with no approved products, so its business model is highly dependent on financing and successful drug development. The main risks are pipeline failure, inability to raise capital, competitive pressure in crowded immunology markets, and potential loss of value if it cannot maintain Nasdaq compliance or protect its intellectual property. Because it relies on third parties for research, clinical operations, and future commercialization, execution risk is also elevated. - **Financing shortfall** [critical] — The company paused R&D and says it may need to raise capital in the immediate term or pursue strategic alternatives. - **Clinical and regulatory failure** [critical] — EQ504, EQ302, and itolizumab may not demonstrate sufficient safety, efficacy, or approvability. - **Competitive displacement** [high] — Multiple companies are developing therapies for the same immuno-inflammatory indications. - **Intellectual property protection** [high] — Weak or narrow IP could allow competitors to copy or block the company’s candidates. - **Nasdaq listing risk** [high] — Management disclosed prior and possible future non-compliance with Nasdaq Capital Market requirements. - **Third-party and cybersecurity dependence** [medium] — The company relies on CROs, data vendors, cloud systems, and manufacturing partners. - May not raise capital in time to continue operations - Pipeline candidates may fail in clinical or regulatory development - Competition in ulcerative colitis and immunology is intense - Third-party dependence creates execution and cybersecurity risk - Nasdaq listing compliance and dilution risk remain material ## Accounting The most important accounting issue is revenue recognition, because historical revenue came from an Ono asset purchase/collaboration arrangement rather than product sales. Investors should also watch R&D expense timing, Australian R&D tax incentive credits, and contingent milestone liabilities that are not expected to come due soon but could affect future cash needs. As a development-stage company with losses and limited revenue, small changes in collaboration accounting or estimates can materially affect reported results. - **Collaboration revenue recognition** — Can create large quarter-to-quarter swings unrelated to product sales - **R&D tax incentive accounting** — Affects reported operating loss and cash flow timing - **Contingent consideration and milestone liabilities** — Could affect future liabilities if development milestones are reached - **Going-concern and financing assumptions** — Can influence disclosure, valuation, and liquidity assessment - Revenue was driven by Ono collaboration/asset purchase accounting - No product sales revenue has been generated to date - Australian R&D tax incentive reduces reported R&D expense - Contingent milestone liabilities exist but are considered remote - Cash burn and going-concern style financing assumptions matter --- *Last updated: 2026-04-28T20:05:17.632330+00:00*